Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Ann Rheum Dis. 2018 Nov 8;78(1):122–130. doi: 10.1136/annrheumdis-2018-213708

Figure 2.

Figure 2.

Time death (Figure 2a)and time to death or organ failure (Figure 2b) from randomization in SLS II. There was no significant difference in the time to death (p=0.627 by log-rank test; Figure 2a), nor the time to death or organ failure (p=0.343 by log-rank test; Figure 2b) for patients randomized to CYC versus MMF in SLS II. The last known date they were known to be alive was used for the survival analysis.